1887

n Health SA Gesondheid - Prescribing of drugs for the treatment of migraine with specific emphasis on sumatriptan : research

USD

 

Abstract

Migraine affects between 5-15% of males and 13, 5-31% of females in South Africa. Little is known about the prescribing patterns of anti-migraine drugs in South Africa. The aim of the study was to investigate the prescribing of drugs for the treatment of migraine (ATC Group N02C), with specific emphasis on sumatriptan, in a primary care patient population in South Africa, making use of a computerised prescription database. A total of 3 011 products for the treatment of migraine at a cost of R451 559 were prescribed to 578 patients in the study over a period of one year (1996) since sumatriptan was the only triptan available in South Africa in 1996. The average age of patients was 48, 40 (SD = 14, 19) years, with 74, 57% of patients between 20 and 59 years of age. Approximately 80% of patients were females. Female patients were prescribed 81, 53% of the products. Most drugs (67, 55%) were for the prophylaxis of migraine, of which clonidine and flunarizine were the most frequently prescribed. Of the drugs prescribed specifically for the management of migraine, sumatriptan (575 prescriptions to 103 patients) was the most frequently prescribed, followed by 400 prescriptions for ergotamine. Tablets were the preferred dosage form. Since migraine affects primarily the economically active sector of the community and its treatment is relatively expensive, pharmacists have an important role to play in managing and counselling migraine sufferers.

Migraine affekteer tussen 5-15% van mans en 13, 5-31% van vroue in Suid-Afrika. Min inligting is beskikbaar oor die voorskryfpatrone van middels teen migraine in Suid-Afrika. Die doel van die studie was om die voorskrywing van middels vir die behandeling van migraine (ATC Groep N02C) in 'n primêre sorg-pasiëntpopulasie te ondersoek, met spesifieke klem op sumatriptan, deur gebruik te maak van 'n gerekenariseerde voorskrif-databasis. 'n Totaal van 3 011 produkte vir die behandeling van migraine teen 'n koste van R451 559 is aan 578 pasiënte in die studie oor 'n tydperk van een jaar (1996) voorgeskryf aangesien sumatriptan die enigste triptan was wat beskikbaar was in 1996. Die gemiddelde ouderdom van die pasiënte was 48, 40 (SD = 14, 19) jaar, met 74, 57% van die pasiënte tussen 20 en 59 jaar oud. Ongeveer 80% van die pasiënte was vroue. Vroulike pasiënte het 81, 53% van die voorgeskrewe produkte ontvang. Die meeste middels (67, 55%) was vir die voorkoming van migraine, waarvan klonidien en flunarisien die meeste voorgeskryf is. Van die middels spesifiek vir die behandeling van migraine, was sumatriptan (575 voorskrifte aan 103 pasiënte) die meeste voorgeskryf, gevolg deur 400 voorskrifte vir ergotamien. Tablette was die gewildste doseervorm. Aangesien migraine hoofsaaklik die ekonomies aktiewe sektor van die gemeenskap beïnvloed en die behandeling relatief duur is, het aptekers 'n belangrike rol om te vervul in die bestuur en konsultering van migrainelyers.

Loading

Article metrics loading...

/content/health/9/4/EJC35313
2004-12-01
2016-12-09
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error